- Home
- IBIO vs GDTC Comparison
IBIO vs GDTC Comparison
Compare IBIO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- GDTC
- Stock Information
- Founded
- IBIO 2008
- GDTC 2018
- Country
- IBIO United States
- GDTC Singapore
- Employees
- IBIO N/A
- GDTC N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- GDTC Health Care
- Exchange
- IBIO Nasdaq
- GDTC Nasdaq
- Market Cap
- IBIO 23.4M
- GDTC 25.1M
- IPO Year
- IBIO N/A
- GDTC 2023
- Fundamental
- Price
- IBIO $2.30
- GDTC $2.17
- Analyst Decision
- IBIO Strong Buy
- GDTC Buy
- Analyst Count
- IBIO 2
- GDTC 1
- Target Price
- IBIO $4.30
- GDTC $5.00
- AVG Volume (30 Days)
- IBIO 97.9K
- GDTC 22.4K
- Earning Date
- IBIO 11-12-2024
- GDTC 01-01-0001
- Dividend Yield
- IBIO N/A
- GDTC N/A
- EPS Growth
- IBIO N/A
- GDTC N/A
- EPS
- IBIO N/A
- GDTC N/A
- Revenue
- IBIO $175,000.00
- GDTC $330,254.00
- Revenue This Year
- IBIO N/A
- GDTC $14.71
- Revenue Next Year
- IBIO N/A
- GDTC N/A
- P/E Ratio
- IBIO N/A
- GDTC N/A
- Revenue Growth
- IBIO 250.00
- GDTC N/A
- 52 Week Low
- IBIO $0.25
- GDTC $1.20
- 52 Week High
- IBIO $6.20
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- IBIO 40.07
- GDTC 47.02
- Support Level
- IBIO $2.40
- GDTC $2.11
- Resistance Level
- IBIO $2.65
- GDTC $2.60
- Average True Range (ATR)
- IBIO 0.21
- GDTC 0.33
- MACD
- IBIO -0.07
- GDTC -0.07
- Stochastic Oscillator
- IBIO 27.49
- GDTC 34.42
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.